TY - JOUR
T1 - Clinical Trial Protocol for LuTectomy
T2 - A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
AU - Dhiantravan, Nattakorn
AU - Violet, John
AU - Eapen, Renu
AU - Alghazo, Omar
AU - Scalzo, Mark
AU - Jackson, Price
AU - Keam, Simon P.
AU - Mitchell, Catherine
AU - Neeson, Paul J.
AU - Sandhu, Shahneen
AU - Williams, Scott G.
AU - Moon, Daniel
AU - Lawrentschuk, Nathan
AU - Azad, Arun
AU - Hofman, Michael S.
AU - Murphy, Declan G.
PY - 2021/3
Y1 - 2021/3
N2 - LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177–radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.
AB - LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177–radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.
UR - http://www.scopus.com/inward/record.url?scp=85097093543&partnerID=8YFLogxK
U2 - 10.1016/j.euf.2020.09.021
DO - 10.1016/j.euf.2020.09.021
M3 - Article
C2 - 33172774
AN - SCOPUS:85097093543
VL - 7
SP - 234
EP - 237
JO - European Urology Focus
JF - European Urology Focus
SN - 2405-4569
IS - 2
ER -